Molecular Partners AG

Detailed Description

Molecular Partners AG operates as a clinical-stage biopharmaceutical company. It is developing Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a COVID-19 antiviral therapeutic candidate to inactivate SARS-CoV-2 that is in Phase II clinical trials. The company also develops MP0310, which is in Phase I clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive solid tumors. In addition, it is developing MP0423, a candidate for treating COVID-19 through a single molecule; MP0533, an immune activator for multi-specific treatment of acute myeloid leukemia; and MP0250, a multi-specific DARPin molecule that targets vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Further, the company develops CD3 T-Cell targeting and peptide MHC therapeutic platforms. Molecular Partners AG has strategic partnerships with Allergan, Inc. and Amgen SA for ophthalmology; collaboration with Novartis AG to develop, manufacture, and commercialize DARPin program; and collaboration with AGC Biologics and Baccinex to support development of anti-COVID-19 program. The company was founded in 2004 and is headquartered in Schlieren, Switzerland.